US Edition
News from endpoints.news
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top endpoints.news News
Tariffs · United StatesThe Trump administration is holding off on its threatened 100 percent tariffs on drugmakers that aren’t building facilities in the U.S., with officials saying the new tax is still being prepared.
See the Story
Trump delays threatened 100 percent tariffs on drugs
67% Center coverage: 15 sources
Novo NordiskSkye Bioscience Inc. (NASDAQ:SKYE) stock sank on Monday after the company released topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab. The nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo (-1.52% vs. -0.26 for placebo, mITT). Preliminary pharmacokinetic analysis showed lower than expected drug exposure of nimacimab, supporting evaluation of higher dosing. Also Read:…See the Story
Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss - Skye Bioscience (NASDAQ:SKYE)
75% Center coverage: 4 sources
